These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 2381619)
41. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma. Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051 [TBL] [Abstract][Full Text] [Related]
42. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers]. Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967 [TBL] [Abstract][Full Text] [Related]
43. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer]. Schelling M; Jänicke F; Senekowitsch R; Lörken A Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138 [No Abstract] [Full Text] [Related]
44. [Tumor markers in epithelial ovarian cancer]. Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857 [TBL] [Abstract][Full Text] [Related]
45. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858 [TBL] [Abstract][Full Text] [Related]
46. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer]. Lahousen M Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273 [TBL] [Abstract][Full Text] [Related]
47. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633 [TBL] [Abstract][Full Text] [Related]
48. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125. Suzuki M; Sekiguchi I; Tamada T Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620 [TBL] [Abstract][Full Text] [Related]
49. [The CA-125 tumor marker in epithelial ovarian cancers of stage I]. Nagele F; Vavra N; Kurz C; Sevelda P Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686 [TBL] [Abstract][Full Text] [Related]
50. [Tumor marker in ovarian cancer]. Komai K; Nishida T Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744 [TBL] [Abstract][Full Text] [Related]
51. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker]. Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183 [TBL] [Abstract][Full Text] [Related]
53. [Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance]. Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Okada K Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):174-80. PubMed ID: 1372032 [TBL] [Abstract][Full Text] [Related]
54. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9]. Zanon C; Alluminio P; Margarita V; Sottimano C; Giuliani F; Neri G; Ballario F Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049 [TBL] [Abstract][Full Text] [Related]
55. [Tumor markers in the monitoring of ovarian cancer]. Xu SX Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861 [TBL] [Abstract][Full Text] [Related]
56. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers]. Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661 [TBL] [Abstract][Full Text] [Related]
57. [Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects]. Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y; Kurachi K Nihon Sanka Fujinka Gakkai Zasshi; 1986 Apr; 38(4):554-60. PubMed ID: 3701144 [TBL] [Abstract][Full Text] [Related]
58. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. Usui N; Suzuki M; Takada M Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732 [TBL] [Abstract][Full Text] [Related]
59. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers]. Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877 [TBL] [Abstract][Full Text] [Related]
60. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]